Astellas
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
January 2, 2024Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …
EMA accepts Astellas’ MAA for Zolbetuximab
July 14, 2023Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …
Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
June 15, 2023Research and Development Astellas, Cullgen, Oncology, protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …
Astellas receives positive CHMP opinion for symptomatic anaemia drug
June 28, 2021Sales and Marketing Astellas, CKD, anaemia
Astellas and FibroGen have announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted …
New NICE recommendation for Astellas prostate cancer drug
June 8, 2021Manufacturing and Production Astellas, NICE, prostate cancer
A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …
Astellas prostate cancer drug gets third approval from MHRA
May 12, 2021Research and Development Astellas, MHRA, cancer research, cancer treatment, pharma, pharma news, prostate cancer
The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making …
Japan approves Astellas and FibroGen’s Evrenzo for chronic kidney disease patients currently not receiving dialysis
November 27, 2020Medical Communications, Sales and Marketing Astellas, Japan, fibrogen
Japan’s Ministry of Health, Labour and Welfare (MHLW) has passed approval for Astellas and FibroGen’s Evrenzo (roxadustat) in the treatment …
China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer
November 6, 2020Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi
China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …
Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer
February 12, 2020Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy
Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …
NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia
January 23, 2020Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia
The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …
FDA approves Astellas injectable antifungal drug for newborns
January 13, 2020Sales and Marketing Astellas, Atellas Pharma, FDA, fungal virsus
The FDA has approved the first antifungal drug to specifically treat invasive candidiasis in newborns. From Astellas, the new drug …
Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash
December 3, 2019Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia
October 28, 2019Sales and Marketing Astellas, Xospata, leukaemia, pharma
Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …
Japan approves Astellas and FibroGen’s Evrenzo for anaemia in dialysis patients
September 23, 2019Sales and Marketing Astellas, anaemia, fibrogen, pharma
Astellas Pharma and FibroGen have revealed that their collaborative drug Evrenzo (roxadustat) has secured marketing authorisation in Japan for the …
Top Ten most popular articles on Pharmafile.com this week!
June 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …
Latest content
FibroFind appoints Lee Borthwick as CEO
